{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:06:38Z","timestamp":1777500398116,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13181-024-00988-0","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:02:34Z","timestamp":1706112154000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Physostigmine for Pediatric Antimuscarinic Poisoning"],"prefix":"10.1007","volume":"20","author":[{"given":"Sarah","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Avera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Penfound","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Overberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2429-2557","authenticated-orcid":false,"given":"Kristine","family":"Na\u00f1agas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"3","key":"988_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12839","volume":"81","author":"AH Dawson","year":"2016","unstructured":"Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81(3):516\u201324.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"988_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MOP.0b013e32802c7be1","volume":"19","author":"N Frascogna","year":"2007","unstructured":"Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr. 2007;19(2):201\u20135.","journal-title":"Curr Opin Pediatr"},{"issue":"7","key":"988_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jama.1995.03530070060031","volume":"274","author":"RS Hoffman","year":"1995","unstructured":"Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness: controversies in the use of a \u2018coma cocktail.\u2019 JAMA. 1995;274(7):562\u20139.","journal-title":"JAMA"},{"issue":"11","key":"988_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0196-0644(80)80232-0","volume":"9","author":"P Pentel","year":"1980","unstructured":"Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9(11):588\u201390.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"988_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0736-4679(03)00169-0","volume":"25","author":"JR Suchard","year":"2003","unstructured":"Suchard JR. Assessing physostigmine\u2019s contraindication in cyclic antidepressant ingestions. J Emerg Med. 2003;25(2):185\u201391.","journal-title":"J Emerg Med"},{"key":"988_CR6","doi-asserted-by":"crossref","unstructured":"Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME, Toxicology Investigators Consortium Case Registry I. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179\u201384.","DOI":"10.1007\/s13181-014-0452-x"},{"issue":"3","key":"988_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s13181-019-00697-z","volume":"15","author":"AM Arens","year":"2019","unstructured":"Arens AM, Kearney T. Adverse effects of physostigmine. J Med Toxicol. 2019;15(3):184\u201391.","journal-title":"J Med Toxicol"},{"issue":"2","key":"988_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15563650.2017.1342828","volume":"56","author":"AM Arens","year":"2018","unstructured":"Arens AM, Shah K, Al-Abri S, Olson KR, Kearney T. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Phila). 2018;56(2):101\u20137.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"988_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15563650.2018.1485154","volume":"57","author":"SP Boley","year":"2019","unstructured":"Boley SP, Olives TD, Bangh SA, Fahrner S, Cole JB. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. Clin Toxicol (Phila). 2019;57(1):50\u20135.","journal-title":"Clin Toxicol (Phila)"},{"issue":"10","key":"988_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/1060028019846654","volume":"53","author":"SP Boley","year":"2019","unstructured":"Boley SP, Stellpflug SJ. A comparison of resource utilization in the management of anticholinergic delirium between physostigmine and nonantidote therapy. Ann Pharmacother. 2019;53(10):1026\u201332.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"988_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0196-0644(00)70057-6","volume":"35","author":"MJ Burns","year":"2000","unstructured":"Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374\u201381.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"988_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0735-6757(98)90003-1","volume":"16","author":"KM Beaver","year":"1998","unstructured":"Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med. 1998;16(5):505\u20137.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"988_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/24734306.2018.1535538","volume":"2","author":"J Rasimas","year":"2018","unstructured":"Rasimas J, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. Toxicology Communications. 2018;2(1):85\u2013101.","journal-title":"Toxicology Communications"},{"issue":"1","key":"988_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1067\/mem.2003.232","volume":"42","author":"AB Schneir","year":"2003","unstructured":"Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med. 2003;42(1):14\u20139.","journal-title":"Ann Emerg Med"},{"issue":"6","key":"988_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ajem.2011.05.015","volume":"30","author":"JB Cole","year":"2012","unstructured":"Cole JB, Stellpflug SJ, Ellsworth H, Harris CR. Reversal of quetiapine-induced altered mental status with physostigmine: a case series. Am J Emerg Med. 2012;30(6):950\u20133.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"988_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajem.2017.07.006","volume":"36","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Armengol C, Wilhoite G, Cumpston KL, Wills BK. Adverse events from physostigmine: an observational study. Am J Emerg Med. 2018;36(1):141\u20132.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"988_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1442-2026.2003.00477.x","volume":"15","author":"GK Isbister","year":"2003","unstructured":"Isbister GK, Oakley P, Dawson AH, Whyte IM. Presumed angel\u2019s trumpet (Brugmansia) poisoning: clinical effects and epidemiology. Emerg Med. 2003;15(4):376\u201382.","journal-title":"Emerg Med"},{"issue":"3","key":"988_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1542\/peds.52.3.449","volume":"52","author":"BH Rumack","year":"1973","unstructured":"Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics. 1973;52(3):449.","journal-title":"Pediatrics"},{"issue":"1","key":"988_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S0265021507001159","volume":"25","author":"W Funk","year":"2008","unstructured":"Funk W, Hollnberger H, Geroldinger J. Physostigmine and anaesthesia emergence delirium in preschool children: a randomized blinded trial. Eur J Anaesthesiol. 2008;25(1):37\u201342.","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"988_CR20","first-page":"1","volume":"58","author":"RB Palmer","year":"2019","unstructured":"Palmer RB, Reynolds KM, Banner W, Randall Bond G, Kauffman RE, Paul IM, et al. Adverse events associated with diphenhydramine in children, 2008\u20132015. Clin Tox (Phila). 2019;58(2):1\u20138.","journal-title":"Clin Tox (Phila)"},{"issue":"3","key":"988_CR21","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1542\/peds.2011-3038","volume":"130","author":"O Derinoz","year":"2012","unstructured":"Derinoz O, Emeksiz HC. Use of physostigmine for cyclopentolate overdose in an infant. Pediatrics. 2012;130(3):e703\u20135.","journal-title":"Pediatrics"},{"issue":"5","key":"988_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MJT.0b013e3181f0cbb4","volume":"19","author":"MM Glatstein","year":"2012","unstructured":"Glatstein MM, Alabdulrazzaq F, Garcia-Bournissen F, Scolnik D. Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature. Am J Therapeutics. 2012;19(5):384\u20138.","journal-title":"Am J Therapeutics"},{"issue":"5","key":"988_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1213\/01.ANE.0000134796.83697.CD","volume":"99","author":"PJ Kulka","year":"2004","unstructured":"Kulka PJ, Toker H, Heim J, Joist A, Jakschik J. Suspected central anticholinergic syndrome in a 6-week-old infant. Anesth Analg. 2004;99(5):1376\u20138.","journal-title":"Anesth Analg"},{"issue":"2","key":"988_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13181-013-0330-y","volume":"10","author":"MA Phillips","year":"2014","unstructured":"Phillips MA, Acquisto NM, Gorodetsky RM, Wiegand TJ. Use of a physostigmine continuous infusion for the treatment of severe and recurrent antimuscarinic toxicity in a mixed drug overdose. J Med Toxicol. 2014;10(2):205\u20139.","journal-title":"J Med Toxicol"},{"issue":"10","key":"988_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/PEC.0b013e3181f39d5b","volume":"26","author":"SH Rhyee","year":"2010","unstructured":"Rhyee SH, Pedapati EV, Thompson J. Prolonged delirium after quetiapine overdose. Pediatr Emer Care. 2010;26(10):754\u20136.","journal-title":"Pediatr Emer Care"},{"issue":"2","key":"988_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1034\/j.1399-6576.2002.460220.x","volume":"46","author":"U Schultz","year":"2002","unstructured":"Schultz U, Idelberger R, Rossiant R, Buhre W. Central anticholinergic syndrome in a child undergoing circumcision. Acta Anaesthesiol Scand. 2002;46(2):224\u20136.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"4","key":"988_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/PEC.0000000000000503","volume":"32","author":"SL Thornton","year":"2016","unstructured":"Thornton SL, Farnaes F, Minns A. Prolonged antimuscarinic delirium in a child due to benztropine exposure treated with multiple doses of physostigmine. Pediatr Emerg Care. 2016;32(4):243\u20135.","journal-title":"Pediatr Emerg Care"},{"issue":"3","key":"988_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/15563657108990496","volume":"4","author":"TL Slovis","year":"1971","unstructured":"Slovis TL, Ott JE, Teitebaum DT, Lipscomb W. Physostigmine therapy in acute tricyclic antidepressant poisoning. Clin Toxicol (Phila). 1971;4(3):451\u20139.","journal-title":"Clin Toxicol (Phila)"},{"key":"988_CR29","unstructured":"Niewi\u00f1ska K, Niewi\u00f1ski Pa, Sokolowski J, Poradowska-Jeszke W, Sok\u00f3lOssowicz A, Wiela-Hoje\u00f1ska A. Administration of acetylcholinesterase inhibitors for central anticholinergic syndrome in pediatric poisoning. Pharmacological Reports. 2007;59(1):226\u201331."},{"issue":"8","key":"988_CR30","first-page":"1","volume":"59","author":"GS Wang","year":"2020","unstructured":"Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2020;59(8):1\u201313.","journal-title":"Clin Toxicol (Phila)"},{"key":"988_CR31","unstructured":"Lovelace B. How U.S. drugmaker Akorn\u2019s closure contributed to the escalating drug shortage crisis. NBC News [Internet]. July 16, 2023 [cited 10\/24\/23] Available from: https:\/\/www.nbcnews.com\/health\/health-news\/akorn-us-drugmaker-closure-escalating-drug-shortage-rcna91402."},{"key":"988_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ajem.2023.02.036","volume":"67","author":"JD Whitledge","year":"2023","unstructured":"Whitledge JD, Soto P, Glowacki KM, Fox ER, Mazer-Amirshahi M. Shortages of agents used to treat antimuscarinic delirium. Am J Emerg Med. 2023;67:163\u20137.","journal-title":"Am J Emerg Med"},{"key":"988_CR33","unstructured":"Anticholinergic. In: Micromedex- Drug Classes [Database on the Internet]. Greenwood Village, CO, USA: IBM Watson Health. 2019; Available from: https:\/\/www.micromedexsolutions.com."},{"issue":"7","key":"988_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00228-013-1499-3","volume":"69","author":"CE Duran","year":"2013","unstructured":"Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. European J Clinical Pharm. 2013;69(7):1485\u201396.","journal-title":"European J Clinical Pharm"},{"issue":"1","key":"988_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","volume":"15","author":"MS Salahudeen","year":"2015","unstructured":"Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15(1):31.","journal-title":"BMC Geriatr"},{"issue":"1","key":"988_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/fcp.12321","volume":"32","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, et al. Atropinic (anticholinergic) burden in antipsychotic-treated patients. Fundam Clin Pharmacol. 2018;32(1):114\u20139.","journal-title":"Fundam Clin Pharmacol"},{"key":"988_CR37","first-page":"755","volume-title":"Goldfrank\u2019s toxicologic emergencies","author":"MA Howland","year":"2019","unstructured":"Howland MA. Physostigmine salicylate. In: Nelson LS, Howland MA, Lewin NA, editors. Goldfrank\u2019s toxicologic emergencies. 11th ed. New York: McGraw Hill Education; 2019. p. 755\u20138.","edition":"11"},{"key":"988_CR38","unstructured":"American Association of Poison Control Centers. NPDS coding users\u2019 manual\u00a9. 2014."},{"issue":"4","key":"988_CR39","first-page":"1","volume":"54","author":"UV Doan","year":"2018","unstructured":"Doan UV, Wu ML, Phua DH, Mendez Rojas B, Yang CC. Datura and Brugmansia plants related antimuscarinic toxicity: an analysis of poisoning cases reported to the Taiwan poison control center. Clin Toxicol (Phila). 2018;54(4):1\u20138.","journal-title":"Clin Toxicol (Phila)"}],"updated-by":[{"DOI":"10.1007\/s13181-024-01007-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000}}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-024-00988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-024-00988-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-024-00988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T14:08:52Z","timestamp":1721657332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-024-00988-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s13181-024-00988-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13181-024-01007-y","asserted-by":"object"}]},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13181-024-01007-y","URL":"https:\/\/doi.org\/10.1007\/s13181-024-01007-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"There were no external sources of funding for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sources of Funding"}}]}}